ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 710

An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival

Basile Tessier-Cloutier1, David Twa2, Eva Baecklund3, Randy Gascoyne4, Nathalie A. Johnson5, Carin Backlin3, Diane L. Kamen6, Ann E. Clarke7, Rosalind Ramsey-Goldman8, Jennifer LF Lee9, Pedro Farinha4 and Sasha Bernatsky10, 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 2Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 4Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada, 5Department of Oncology, McGill University, Montreal, QC, Canada, 6Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 7Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 8FSM, Northwestern University, Chicago, IL, 9Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 10Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cancer, Malignancy and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal centre B-cell (GCB) indicating poorer prognosis in the general population. We studied COO subtyping in SLE patients diagnosed with DLBCL, and overall survival.

Methods: We evaluated 20 cases of SLE with DLBCL. In tissue microarrays, immunohistochemistry analysis was performed (BCL2, MYC, BCL6, CD10, CD20, FOXP1, GCET1, MUM1). We examined associations between molecular and clinical features, including overall survival (time to death, all-cause).

Results: Of the 20 DLBCL SLE cases (Table 1), 12/20 cases (60%) were classified as non-germinal centre B-cell (GCB) whereas 8/20(40%) were classified as GCB using Hans or Choi algorithms. MYC and BCL2 protein expression was positive in 6/20 (30%) and 8/20(40%) SLE cases, respectively with 2/20 (10%) co-expressing both markers.

The median survival for all 20 cases was 39 (mean 64) months. As expected, non-GCB cases had worse survival. In both univariate and multivariable Cox proportional hazards models, both non-GBC type and nodal status (any nodal involvement versus none) were associated with lower survival (Table 2). Stratification of cases by nodal status revealed that SLE duration at DLBCL diagnosis was much longer in cases presenting with nodal-only involvement and that BCL2 expression tended to be greater in patients presenting with extra-nodal involvement only. We were unable to detect any molecular or clinical features differing by COO subtype. SLE patients presenting exclusively with extranodal DLBCL were associated with better survival despite higher BCL2 protein expression (which normally indicates poor prognosis).

Conclusion: We present novel data characterizing DLBCL in SLE. Sixty percent of the DLBCL in SLE patients were non-GCB. The nodal and extranodal distribution was similar between patient with SLE and the general population, but extranodal disease occurred more often with short SLE duration and was associated with longer over-all survival. Since non-GCB DLBCL rely on the activation of the NF-κB and JAK-STAT pathways, future assessments of the links between SLE and DLBCL could focus on genetic factors related to the TNF superfamily (TNFSF4), TNF-α, TNF Alpha Induced Protein 3, and other related pathways.

Table 1. Descriptive features of the SLE-DLBCL (n=20) subjects

Variable

Median [IQR]

Sex (female)

2/20 (90)

Age at SLE Diagnosis

45 [36-54]

Age at time of DLBCL diagnosis

58 [48-66]

SLE duration at DLBCL diagnosis

11 [5-18]

Variable

N (%)

Diagnosed after 1991

12 (60)

Nodal-only involvement

10 (50)

Only extranodal involvement

7 (35)

MYC positive

6 (30)

BCL2 positive

8 (40)

BCL6 positive

7 (35)

Dual positive, MYC and BCL-2

2 (10)

Non-germinal B-cell origin (Hans)

12 (60)

Table 2. Cox proportional hazards ratio (HR) for survival in SLE-DLBCL (n=20).

Variable (reference)

Unadjusted HR (95%CI)

Adjusted* HR (95%CI)

Sex (female)

2.64 (0.95-7.37)

4.49 (1.06-19.0)

Year of DLBCL diagnosis (years)

0.97 (0.92-1.02)

0.94 (0.88-1.01)

Any nodal-involvement

0.29 (0.10-0.98)

0.09 (0.03-0.26)

Non-germinal B-cell origin cell type(Hans)

0.28 (0.08-0.93)

0.08 (0.02-0.43)

*The adjusted model included all four variables in this table.


Disclosure: B. Tessier-Cloutier, None; D. Twa, None; E. Baecklund, None; R. Gascoyne, None; N. A. Johnson, None; C. Backlin, None; D. L. Kamen, None; A. E. Clarke, Bristol-Myers Squibb, 5,AstraZeneca, 5,Exagen Diagnostics, 5,AstraZeneca, 9,Celgene Corporation, 9; R. Ramsey-Goldman, Exagen Diagnostics, Inc, 2; J. L. Lee, None; P. Farinha, None; S. Bernatsky, None.

To cite this abstract in AMA style:

Tessier-Cloutier B, Twa D, Baecklund E, Gascoyne R, Johnson NA, Backlin C, Kamen DL, Clarke AE, Ramsey-Goldman R, Lee JL, Farinha P, Bernatsky S. An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/an-analysis-of-cell-of-origin-in-diffuse-large-b-cell-lymphoma-in-systemic-lupus-erythematosus-including-molecular-and-clinical-factors-associated-with-survival/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-analysis-of-cell-of-origin-in-diffuse-large-b-cell-lymphoma-in-systemic-lupus-erythematosus-including-molecular-and-clinical-factors-associated-with-survival/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology